Supplements for Hot Flashes: What the Evidence Shows

Hot flashes and night sweats are often grouped as vasomotor symptoms. A relevant trial should measure an outcome such as hot-flash frequency, severity, or a defined symptom score. A change in sleep, mood, nutrient status, or a broad menopause questionnaire does not by itself prove that hot flashes improved.

Before-and-after testimonials are especially hard to interpret because symptoms can fluctuate and improvement also occurs in placebo groups. In pooled data from two randomized hot-flash trials, 33% of placebo participants achieved at least a 50% reduction in frequency by week eight. ¹ That does not make symptoms imaginary. It shows why a comparison group and a clearly defined outcome matter.

The finished product matters too. Evidence for a named, standardized preparation cannot be transferred automatically to a different extract, a powder, or a multi-ingredient blend that merely shares one familiar ingredient name.

This guide stays in that narrow lane. The broader perimenopause and menopause supplement guide separates hot flashes from sleep, bone-health nutrition, muscle, and other outcomes that require different evidence.

The Menopause Society’s 2023 position statement does not recommend supplements or herbal remedies for vasomotor symptoms. It also does not recommend soy foods, soy extracts, or equol for this purpose, because the evidence was considered limited or inconsistent. ²

NICE’s current guideline retains a 2015 recommendation that there is some evidence that isoflavones or black cohosh may relieve vasomotor symptoms, while stressing that preparations vary, safety is uncertain, and medicine interactions have been reported. ³

The latest International Menopause Society recommendations also allow consideration of specific preparations. They discuss soy-derived isoflavones standardized to 40 to 100 mg and black cohosh, while their short-term safety statement applies specifically to an isopropanolic black cohosh extract used for three to six months. ⁴ Those details describe the guideline evidence, not a personal dose or a blanket approval of every retail product.

The 2026 systematic review that informed the IMS update found a moderate-certainty signal for black cohosh on selected outcomes, but rated most complementary-therapy evidence low or very low certainty. ⁵ Different evidence windows, included products, outcomes, and thresholds for a recommendation help explain the split.

Soy foods, soy protein, generic soy extract, quantified isoflavones, and equol are different interventions. NCCIH describes a possible small reduction in hot-flash frequency or severity from soy isoflavones, but also notes inconsistent results and limitations in the evidence. ⁶

A 2025 systematic review of perimenopausal participants found a small improvement in the combined menopause-symptom result, but no statistically significant effect on hot flashes, excessive sweating, or the vasomotor-symptom result. The authors cautioned that samples were small. ⁷ That is why soy should not be described as a guaranteed or universally best hot-flash supplement.

On the label, start with the actual isoflavone amount, not the largest soy-related number on the panel. A line that lists 300 mg of soy extract does not reveal 300 mg of isoflavones. The product needs to state the isoflavone amount or provide clear standardization information before that active amount can be evaluated. The Soy Isoflavones guide covers this distinction in more detail.

Black cohosh is not one uniform intervention. Research has used particular extracts, doses, treatment periods, and sometimes combination products. A 2023 meta-analysis reported a small favorable hot-flash effect, but its analysis combined studies of black cohosh alone with combination regimens. ⁸

A useful label identifies Actaea racemosa, sometimes listed under its synonym Cimicifuga racemosa, and names the root or rhizome. It should distinguish a powder from an extract and disclose the individual amount, extraction details when provided, and any exact standardization statement. These facts help identify the preparation; they do not guarantee the same result as a studied product.

Product identity is a practical limitation, not a cosmetic detail. NCCIH notes that some products sold as black cohosh have contained the wrong herb or undeclared mixtures. ⁹ A Supplement Facts panel can disclose the intended botanical and preparation, but it cannot confirm physical identity, purity, or batch consistency. See the full Black Cohosh label guide.

Magnesium is an essential nutrient, but that role does not establish it as a hot-flash treatment. A multicenter placebo-controlled trial in 289 postmenopausal breast-cancer survivors tested two magnesium oxide regimens. Neither improved hot-flash frequency or the combined hot-flash score, and diarrhea was more common with magnesium. ¹⁰

This trial tested one magnesium compound in a specific population, so it is not a final test of every form in every person. It also provides no sound basis for promoting magnesium glycinate, citrate, or another form as a proven hot-flash alternative. Sleep, dietary adequacy, and vasomotor symptoms are separate questions.

U.S. Supplement Facts panels declare the amount of elemental magnesium, with the source form usually shown in parentheses. ¹¹ Compare that elemental amount across the complete daily serving, not the compound weight or a front-label capsule claim. Read the Magnesium guide and elemental magnesium explainer for the label mechanics.

Red Clover supplies isoflavones, but it should not be treated as interchangeable with soy isoflavones. NCCIH describes the clinical findings as inconsistent, and the latest IMS recommendations judged the evidence insufficient to recommend red clover for reducing hot-flash frequency. ^{4 12}

A 2026 meta-analysis of nine randomized trials reported a small to moderate statistical reduction in hot flashes. ¹³ It was published after the evidence window for the current IMS recommendations, so it is a new signal rather than proof that every red clover product is now established. The exact extract and disclosed isoflavone content still matter.

Multi-ingredient menopause formulas add another problem. Under U.S. labeling rules, a proprietary blend may disclose only the blend’s total weight while listing its components in descending order by weight. ¹⁴ That confirms the ingredients are listed, but not how much black cohosh, red clover, or another component is present. Read What Is a Proprietary Blend? for the full label context.

A credible comparison starts with the specific hot-flash outcome and works backward to the label. It does not begin with the largest number or the strongest front-label phrase. The table below separates what a line can disclose from what it cannot prove.